
Paving the way for innovation in disease detection and life science research
Complete this form to qualify for a FREE Logix Smart™ ZIKA kit
Co-Diagnostics, Inc (NASDAQ: CODX) is a molecular diagnostics company with a unique, patented and patent-pending approach to PCR technology
The Logix Smart™ Zika Virus (ZIKV) test uses our patented CoPrimer™technology to detect the presence or absence of ribonucleic acid (RNA) of Zika virus in a real-time RT-PCR kit that targets conserved regions in the Zika virus genome.
The test operates using a single step reverse transcription real-time PCR reaction in serum or plasma samples, collected alongside with urine, from patients suspected of Zika fever or Zika disease during acute stages of the disease that happen between 2 to 20 days after the onset of the symptomatic or non-symptomatic infection. The amplified product is then detected within 40 cycles by fluorescent dyes FAM (green) or Cal Fluor 610 (orange).
Logix Smart™ ZIKA Kit


- Each Logix Smart Zika Virus Test kit contains a complete, ready-to-use master mix.
- A human RNaseP gene marker serves as an Internal Positive Control (IPC) to monitor the quality of each reaction and is designed to also detect inadequate samples.
Nuclease Free Water is also provided for a negative control.
Each kit provides reagents sufficient for 100 reactions.
We are passionate about providing the most robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications

Please send me more information about research solutions

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.
COMPANY
LATEST NEWS RELEASE
Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share
Salt Lake City, Utah – November 2, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that following the discovery of an incorrectly...
ARCHIVE

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
COMPANY
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.